Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05871099 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 20, 2024 to Dec 2030
    • Study completion date: Nov 20, 2039 to Dec 2030
    • Collaborators revised (22)
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving the 5-year overall survival rate and decrease the peritoneal metastases rate of patients with advanced gastric cancer underwent Laparoscopic Gastrectomy with D2 Lymphadenectomy. Participants will be divided into two groups, Experimental group received laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6\~8 cycles; and Control group received laparoscopic (robotic) D2 surgery plus systemic chemotherapy 6\~8 cycles.
Trial Details
NCT Number NCT05871099
Lead Sponsor The Affiliated Hospital of Qingdao University
Collaborators: Shandong Cancer Hospital and Institute, Chinese PLA General Hospital, Zibo Central Hospital, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Jinan Central Hospital, Qilu Hospital of Shandong University, Yantai Yuhuangding Hospital, Nanfang Hospital, Southern Medical University, Shandong First Medical University, The First Affiliated Hospital of Nanchang University, Hebei Medical University Fourth Hospital, Peking University Cancer Hospital & Institute, Peking University People's Hospital, Tianjin Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Zhongnan Hospital, Brigham and Women's Hospital, Second Xiangya Hospital of Central South University, Weihai Municipal Hospital, Mountain University Cancer Hospital, Ruijin Hospital
Conditions
(from sponsor)		 Gastric Cancer
Related terms Stomach Neoplasms
Enrollment 616 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov